For The Prevention and Treatment of Diseases Affecting Mankind

Site Map | Copyright | Home

 

Product Overview

Virionics is a privately-held biotechnology asset holding company that was founded to develop, manufacture and commercialize affordable drug therapies and vaccines to prevent and treat diseases affecting mankind.

Virionics is the parent company of C-VIRION CORPORATION (C-VIRION), AbGenesis, Inc., and PharmaBioPro and this structure serves as a value-creating vehicle for new product development opportunities for the parent company and each subsidiary.

C-VIRION is focused on the clinical and regulatory development and the commercialization of recombinant protein products for the treatment and prevention of hepatitis C viral disease (HCV), AbGenesis utilizes immuno-therapies to fight disease through antibody-based therapeutics, and PharmaBioPro is commercializing and marketing recently off-patent, generic anti-viral and cancer drug therapeutics.

C-VIRION is preparing to enter clincial trials with its lead product, C-Vax, in a Phase I/II clinical study in late 2009. C-Vax is being developed for the prevention and treatment of hepatitis C infection. Several other products are in the preclinical pipeline for treatment of chronic hepatitis C infection.

AbGenesis is conducting preclinical research with drug candidates in the therapeutic areas of Alzheimer's Disease, cancer, chronic pain, asthma, hormone ablation, d rug addiction, obesity, and other major disease categories. This "platform technology" for making "immune-drugs" to treat a variety of therapeutic areas will generate a tremendous pipeline of products and high "blockbuster" potential.

PharmaBioPro has a portfolio of generic drugs manufacturered in India and China that will be introduced as low-cost generics into the North American and European markets. Our experienced business development staff will utilize their contacts to attract corporate partners to fund product-specific programs in exchange for marketing rights in certain market regions. The Company will be generating revenue from product sales starting in Q2 2010.

The product pipeline table below lists our VLP programs and their stage of clinical development:

Product Pipeline

Product
Pre-Clinical
Phase I
Phase II
Phase III
Market Approval
Genzarbin™
PharmaBioPro's generic Gemcitabine - oncology drug
             
C-Vax™
C-VIRION's Vaccine for HCV Prevention
             
C-Rx™
C-VIRION's Vaccine for HCV Therapy
             
C-Immune™
C-VIRION's antibody product for Liver Transplantation
             
Abloid™
AbGenesis' anti-amyloid vaccine for Alzheimer's
             

 

 
 

• Product Overview
Virus-Like Particles (VLPs)
PharmaBioPro Drugs
C-VIRION C-VAX
Abgenesis Abloid